These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 24943810)
21. Effect of TLR4 and B7-H1 on immune escape of urothelial bladder cancer and its clinical significance. Wang YH; Cao YW; Yang XC; Niu HT; Sun LJ; Wang XS; Liu J Asian Pac J Cancer Prev; 2014; 15(3):1321-6. PubMed ID: 24606459 [TBL] [Abstract][Full Text] [Related]
22. There and back again: An immunotherapy tale. Guo Y; Krupnick AS J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610 [No Abstract] [Full Text] [Related]
23. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer. Ma YF; Chen C; Li D; Liu M; Lv ZW; Ji Y; Xu J Oncotarget; 2017 Jan; 8(5):7614-7624. PubMed ID: 27935862 [TBL] [Abstract][Full Text] [Related]
24. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses. Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y MAbs; 2018; 10(2):315-324. PubMed ID: 29182441 [TBL] [Abstract][Full Text] [Related]
25. Immune Checkpoint Inhibitors in AML-A New Frontier. Thummalapalli R; Knaus HA; Gojo I; Zeidner JF Curr Cancer Drug Targets; 2020; 20(7):545-557. PubMed ID: 32316893 [TBL] [Abstract][Full Text] [Related]
26. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches. Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277 [TBL] [Abstract][Full Text] [Related]
27. Acetylcholine promotes the self-renewal and immune escape of CD133+ thyroid cancer cells through activation of CD133-Akt pathway. Wang Z; Liu W; Wang C; Li Y; Ai Z Cancer Lett; 2020 Feb; 471():116-124. PubMed ID: 31830559 [TBL] [Abstract][Full Text] [Related]
28. Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer. Wahba J; Natoli M; Whilding LM; Parente-Pereira AC; Jung Y; Zona S; Lam EW; Smith JR; Maher J; Ghaem-Maghami S Cancer Immunol Immunother; 2018 Nov; 67(11):1753-1765. PubMed ID: 30167862 [TBL] [Abstract][Full Text] [Related]
29. Development of PARP and Immune-Checkpoint Inhibitor Combinations. Stewart RA; Pilié PG; Yap TA Cancer Res; 2018 Dec; 78(24):6717-6725. PubMed ID: 30498083 [TBL] [Abstract][Full Text] [Related]
30. Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma. Zhou B; Yan J; Guo L; Zhang B; Liu S; Yu M; Chen Z; Zhang K; Zhang W; Li X; Xu Y; Xiao Y; Zhou J; Fan J; Hung MC; Li H; Ye Q Theranostics; 2020; 10(14):6530-6543. PubMed ID: 32483468 [TBL] [Abstract][Full Text] [Related]
31. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Liu J; Hamrouni A; Wolowiec D; Coiteux V; Kuliczkowski K; Hetuin D; Saudemont A; Quesnel B Blood; 2007 Jul; 110(1):296-304. PubMed ID: 17363736 [TBL] [Abstract][Full Text] [Related]
32. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer. Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778 [TBL] [Abstract][Full Text] [Related]
33. The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer. Zhang S; Bai X; Shan F Int Immunopharmacol; 2020 Mar; 80():106247. PubMed ID: 32007710 [TBL] [Abstract][Full Text] [Related]
34. Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. Qin A; Coffey DG; Warren EH; Ramnath N Cancer Med; 2016 Sep; 5(9):2567-78. PubMed ID: 27416962 [TBL] [Abstract][Full Text] [Related]
35. Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. Mavratzas A; Seitz J; Smetanay K; Schneeweiss A; Jäger D; Fremd C Future Oncol; 2020 Jan; 16(3):4439-4453. PubMed ID: 31829043 [TBL] [Abstract][Full Text] [Related]